Closing in on Cancer
We are Merus
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.Technology Download Merus' Corporate Presentation
Board of Directors
Investors & Media
For more information and the latest news about Merus N.V., please visit our Investor Relations section by clicking the button below.
[This section of the website is under construction. You will be temporarily re-routed to Merus’ old website.]Investors & Media